|
시장보고서
상품코드
1867493
세계의 마이크로바이옴 의약품 : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)Microbiome Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031 |
||||||
QYResearch
세계의 마이크로바이옴 의약품 시장 규모는 2024년에 5억 6,800만 달러로 평가되었고, 2025-2031년의 예측 기간에 CAGR 30.1%로 성장하여 2031년까지 32억 9,600만 달러에 이를 것으로 예측됩니다.
마이크로바이옴 의약품은 인간의 공생 미생물총과 그 대사산물을 기반으로 개발된 새로운 치료제의 범주를 말합니다. 여기에는 생수처리제(LBP), 미생물총 유래 대사산물, 합성미생물제제, 마이크로바이옴을 표적으로 하는 저분자 의약품 등이 포함됩니다. 이러한 치료법은 장, 피부, 호흡기 등 숙주의 미세 생태 환경을 조절하여 면역 균형 회복, 대사 조절, 감염, 염증성 장질환, 대사 장애, 신경정신질환, 암 등 다양한 질환의 치료를 목표로 하고 있습니다. 마이크로바이옴 과학과 합성생물학의 비약적인 발전이 가속화되면서 마이크로바이옴 의약품은 정밀의료의 핵심 축으로 부상하고 있으며, 치료 패러다임을 '미생물을 죽이는 것'에서 '미생물을 활용하는 것'으로 전환하여 전신적인 치료 효과를 가져오고 있습니다.
정밀의료의 개념이 전 세계적으로 진화하고 있는 가운데, 마이크로바이옴 의약품은 바이오의약품 혁신의 새로운 전략적 개척지로 빠르게 부상하고 있습니다. 여러 국가의 규제 당국은 살아있는 미생물 기반 제품에 대한 전용 심사 경로를 구축하여 임상 적용을 가속화하고 있습니다. 각 회사의 연례 보고서에 따르면, 여러 임상 3상 후보물질이 상업화 단계에 근접하고 있어 시장 전환점이 임박했음을 알 수 있습니다. 한편, 합성생물학의 발전으로 안정적인 발현 플랫폼을 갖춘 설계 미생수처리제가 가능해지면서 미생물총 치료는 분변이식에서 표준화된 의약품으로 변모하고 있습니다. 만성질환, 면역질환, 종양학 분야 수요 증가를 배경으로 전 세계적인 투자와 연구개발 자원이 이 혁신적인 분야에 집중되고 있습니다.
마이크로바이옴 의약품은 혁신적 잠재력에도 불구하고 아직 도입 초기 단계에 있으며, 기술 및 규제 측면에서 불확실성에 직면해 있습니다. 실제 임상 데이터에서 일부 초기 단계 제품에서 환자 간 변동성이 높고, 효능에 일관성이 없는 것으로 밝혀져 임상 표준화의 과제가 되고 있습니다. 생물학적 제제의 제조, 콜드체인 물류, 품질 관리 요구 사항은 특히 생산 확대에 있어 높은 기술적 장벽을 부과하고 있습니다. 또한, 많은 지역에서는 상환 프레임워크와 임상 자금 조달 메커니즘이 미개발되어 있어 단기적으로 시장 침투가 지연되고 있습니다.
수요 측면에서는 숙주와 마이크로바이옴의 상호 작용에 대한 깊은 지식이 '보조적 프로바이오틱스'에서 '중재적 처방약'으로의 전환을 촉진하고 있습니다. 의사들은 특히 난치성 클로스트리디움 디피실 감염, 궤양성 대장염, 자폐스펙트럼 장애, 2형 당뇨병 환자들을 위해 마이크로바이옴 기반 치료법에 대한 관심이 높아지고 있습니다. 주요 병원들은 제약회사와 제휴하여 공동 개발 및 실제 임상 연구를 수행함으로써 학술 시험에서 일상적인 임상 적용으로의 전환을 촉진하고 있습니다. 더 많은 후보 약물이 중요한 시험 단계에 도달함에 따라, 마이크로바이옴 의약품은 세계 처방약 시장에서 독특하고 잠재력이 높은 부문을 구축할 준비가 되어 있습니다.
이 보고서는 마이크로바이옴 의약품 세계 시장에 대한 종합적인 분석을 제공하는 것을 목표로 합니다. 총 매출액, 주요 기업의 시장 점유율과 순위에 초점을 맞추어 지역별, 국가별, 유형별, 증상별 마이크로바이옴 의약품 분석을 포함하고 있습니다.
마이크로바이옴 의약품 시장 규모, 추정 및 예측은 매출액 기준으로 제시되며, 2024년을 기준 연도로 하여 2020년부터 2031년까지의 기간의 과거 데이터와 예측 데이터를 포함합니다. 정량적 분석과 정성적 분석을 통해 독자들이 비즈니스/성장 전략을 수립하고, 시장 경쟁 구도를 평가하고, 현재 시장에서의 자사 위치를 분석하고, 마이크로바이옴 의약품에 대한 정보에 입각한 비즈니스 의사결정을 내릴 수 있도록 돕습니다.
시장 세분화
기업별
- Seres Therapeutics
- Assembly Biosciences
- Synthetic Biologics
- Finch Therapeutics
- PureTech
- Synlogic
- Enterome BioScience
- 4D Pharma
- Second Genome
- Ferring
- C3 Jian
- Rebiotix
- MicroBiome Therapeutics LLC
- Metabiomics
- Ritter Pharmaceuticals
- Symberix
- OpenBiome
- Azitra
- Symbiotix Biotherapies
- Vedanta Biosciences
- Metabogen
유형별 부문
- 경구 제형
- 장용성 캡슐
증상 별 부문
- 위장 질환
- 자가면역 질환
- 당뇨병
- 암
- 기타
지역별
- 북미
- 미국
- 캐나다
- 아시아태평양
- 중국
- 일본
- 한국
- 동남아시아
- 인도
- 호주
- 기타 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 네덜란드
- 북유럽 국가
- 기타 유럽
- 라틴아메리카
- 멕시코
- 브라질
- 기타 라틴아메리카
- 중동 및 아프리카
- 튀르키예
- 사우디아라비아
- 아랍에미리트(UAE)
- 기타 중동 및 아프리카
The global market for Microbiome Drugs was estimated to be worth US$ 568 million in 2024 and is forecast to a readjusted size of US$ 3296 million by 2031 with a CAGR of 30.1% during the forecast period 2025-2031.
Microbiome Drugs refer to a new class of therapeutic agents developed based on human commensal microbiota and their metabolites. These include live biotherapeutic products (LBPs), microbiota-derived metabolites, synthetic microbial formulations, and microbiome-targeted small molecule drugs. By modulating the host's microecological environment-such as the gut, skin, or respiratory tract-these therapies aim to restore immune balance, regulate metabolism, and treat a broad spectrum of diseases including infectious conditions, inflammatory bowel diseases, metabolic disorders, neuropsychiatric illnesses, and cancers. As breakthroughs in microbiome science and synthetic biology continue to accelerate, microbiome drugs are emerging as a core pillar of precision medicine-transforming treatment paradigms from "killing microbes" to "leveraging microbes" for systemic therapeutic benefit.
As the concept of precision medicine continues to evolve globally, microbiome drugs are rapidly emerging as a new strategic frontier in biopharmaceutical innovation. Regulatory authorities in multiple countries have established dedicated review pathways for live microbiome-based products, accelerating clinical translation. According to annual reports from companies several Phase III candidates are approaching commercialization, signaling an imminent market inflection point. Meanwhile, advances in synthetic biology are enabling engineered microbial therapeutics with stable expression platforms, transforming microbiota therapies from fecal transplants into standardized pharmaceuticals. With chronic diseases, immune disorders, and oncology driving demand, global investment and R&D resources are converging toward this transformative sector.
Despite their disruptive potential, microbiome drugs remain in the early adoption phase, facing both technological and regulatory uncertainty. Real-world data reveal high inter-patient variability and inconsistent efficacy in some early-stage products, posing challenges for clinical standardization. Manufacturing, cold-chain logistics, and quality control requirements for live biotherapeutics impose high technical barriers, particularly in scaling up production. In addition, reimbursement frameworks and clinical funding mechanisms are still underdeveloped in many regions, slowing broad market penetration in the short term.
On the demand side, deeper insights into host-microbiome interactions are driving a shift from "supplemental probiotics" to "interventional prescription drugs." Physicians are increasingly open to microbiome-based therapies, especially for patients with refractory Clostridium difficile infections, ulcerative colitis, autism spectrum disorders, and type 2 diabetes. Leading hospitals are partnering with pharma companies to conduct joint development and real-world studies, fostering a transition from academic trials to routine clinical use. As more candidates reach critical trial milestones, microbiome drugs are poised to establish a distinct and high-potential segment within the global prescription drug market.
This report aims to provide a comprehensive presentation of the global market for Microbiome Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Microbiome Drugs by region & country, by Type, and by Symptom.
The Microbiome Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Microbiome Drugs.
Market Segmentation
By Company
- Seres Therapeutics
- Assembly Biosciences
- Synthetic Biologics
- Finch Therapeutics
- PureTech
- Synlogic
- Enterome BioScience
- 4D Pharma
- Second Genome
- Ferring
- C3 Jian
- Rebiotix
- MicroBiome Therapeutics LLC
- Metabiomics
- Ritter Pharmaceuticals
- Symberix
- OpenBiome
- Azitra
- Symbiotix Biotherapies
- Vedanta Biosciences
- Metabogen
Segment by Type
- Oral Dosage Form
- Enteric Capsules
Segment by Symptom
- Gastrointestinal Disorders
- Autoimmune Disorders
- Diabetes
- Cancer
- Others
By Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Microbiome Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Symptom, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Microbiome Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Microbiome Drugs in country level. It provides sigmate data by Type, and by Symptom for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
- 1.1 Microbiome Drugs Product Introduction
- 1.2 Global Microbiome Drugs Market Size Forecast (2020-2031)
- 1.3 Microbiome Drugs Market Trends & Drivers
- 1.3.1 Microbiome Drugs Industry Trends
- 1.3.2 Microbiome Drugs Market Drivers & Opportunity
- 1.3.3 Microbiome Drugs Market Challenges
- 1.3.4 Microbiome Drugs Market Restraints
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Competitive Analysis by Company
- 2.1 Global Microbiome Drugs Players Revenue Ranking (2024)
- 2.2 Global Microbiome Drugs Revenue by Company (2020-2025)
- 2.3 Key Companies Microbiome Drugs Manufacturing Base Distribution and Headquarters
- 2.4 Key Companies Microbiome Drugs Product Offered
- 2.5 Key Companies Time to Begin Mass Production of Microbiome Drugs
- 2.6 Microbiome Drugs Market Competitive Analysis
- 2.6.1 Microbiome Drugs Market Concentration Rate (2020-2025)
- 2.6.2 Global 5 and 10 Largest Companies by Microbiome Drugs Revenue in 2024
- 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Microbiome Drugs as of 2024)
- 2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
- 3.1 Introduction by Type
- 3.1.1 Oral Dosage Form
- 3.1.2 Enteric Capsules
- 3.2 Global Microbiome Drugs Sales Value by Type
- 3.2.1 Global Microbiome Drugs Sales Value by Type (2020 VS 2024 VS 2031)
- 3.2.2 Global Microbiome Drugs Sales Value, by Type (2020-2031)
- 3.2.3 Global Microbiome Drugs Sales Value, by Type (%) (2020-2031)
4 Segmentation by Symptom
- 4.1 Introduction by Symptom
- 4.1.1 Gastrointestinal Disorders
- 4.1.2 Autoimmune Disorders
- 4.1.3 Diabetes
- 4.1.4 Cancer
- 4.1.5 Others
- 4.2 Global Microbiome Drugs Sales Value by Symptom
- 4.2.1 Global Microbiome Drugs Sales Value by Symptom (2020 VS 2024 VS 2031)
- 4.2.2 Global Microbiome Drugs Sales Value, by Symptom (2020-2031)
- 4.2.3 Global Microbiome Drugs Sales Value, by Symptom (%) (2020-2031)
5 Segmentation by Region
- 5.1 Global Microbiome Drugs Sales Value by Region
- 5.1.1 Global Microbiome Drugs Sales Value by Region: 2020 VS 2024 VS 2031
- 5.1.2 Global Microbiome Drugs Sales Value by Region (2020-2025)
- 5.1.3 Global Microbiome Drugs Sales Value by Region (2026-2031)
- 5.1.4 Global Microbiome Drugs Sales Value by Region (%), (2020-2031)
- 5.2 North America
- 5.2.1 North America Microbiome Drugs Sales Value, 2020-2031
- 5.2.2 North America Microbiome Drugs Sales Value by Country (%), 2024 VS 2031
- 5.3 Europe
- 5.3.1 Europe Microbiome Drugs Sales Value, 2020-2031
- 5.3.2 Europe Microbiome Drugs Sales Value by Country (%), 2024 VS 2031
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific Microbiome Drugs Sales Value, 2020-2031
- 5.4.2 Asia Pacific Microbiome Drugs Sales Value by Region (%), 2024 VS 2031
- 5.5 South America
- 5.5.1 South America Microbiome Drugs Sales Value, 2020-2031
- 5.5.2 South America Microbiome Drugs Sales Value by Country (%), 2024 VS 2031
- 5.6 Middle East & Africa
- 5.6.1 Middle East & Africa Microbiome Drugs Sales Value, 2020-2031
- 5.6.2 Middle East & Africa Microbiome Drugs Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
- 6.1 Key Countries/Regions Microbiome Drugs Sales Value Growth Trends, 2020 VS 2024 VS 2031
- 6.2 Key Countries/Regions Microbiome Drugs Sales Value, 2020-2031
- 6.3 United States
- 6.3.1 United States Microbiome Drugs Sales Value, 2020-2031
- 6.3.2 United States Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
- 6.3.3 United States Microbiome Drugs Sales Value by Symptom, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Microbiome Drugs Sales Value, 2020-2031
- 6.4.2 Europe Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
- 6.4.3 Europe Microbiome Drugs Sales Value by Symptom, 2024 VS 2031
- 6.5 China
- 6.5.1 China Microbiome Drugs Sales Value, 2020-2031
- 6.5.2 China Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
- 6.5.3 China Microbiome Drugs Sales Value by Symptom, 2024 VS 2031
- 6.6 Japan
- 6.6.1 Japan Microbiome Drugs Sales Value, 2020-2031
- 6.6.2 Japan Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
- 6.6.3 Japan Microbiome Drugs Sales Value by Symptom, 2024 VS 2031
- 6.7 South Korea
- 6.7.1 South Korea Microbiome Drugs Sales Value, 2020-2031
- 6.7.2 South Korea Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
- 6.7.3 South Korea Microbiome Drugs Sales Value by Symptom, 2024 VS 2031
- 6.8 Southeast Asia
- 6.8.1 Southeast Asia Microbiome Drugs Sales Value, 2020-2031
- 6.8.2 Southeast Asia Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
- 6.8.3 Southeast Asia Microbiome Drugs Sales Value by Symptom, 2024 VS 2031
- 6.9 India
- 6.9.1 India Microbiome Drugs Sales Value, 2020-2031
- 6.9.2 India Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
- 6.9.3 India Microbiome Drugs Sales Value by Symptom, 2024 VS 2031
7 Company Profiles
- 7.1 Seres Therapeutics
- 7.1.1 Seres Therapeutics Profile
- 7.1.2 Seres Therapeutics Main Business
- 7.1.3 Seres Therapeutics Microbiome Drugs Products, Services and Solutions
- 7.1.4 Seres Therapeutics Microbiome Drugs Revenue (US$ Million) & (2020-2025)
- 7.1.5 Seres Therapeutics Recent Developments
- 7.2 Assembly Biosciences
- 7.2.1 Assembly Biosciences Profile
- 7.2.2 Assembly Biosciences Main Business
- 7.2.3 Assembly Biosciences Microbiome Drugs Products, Services and Solutions
- 7.2.4 Assembly Biosciences Microbiome Drugs Revenue (US$ Million) & (2020-2025)
- 7.2.5 Assembly Biosciences Recent Developments
- 7.3 Synthetic Biologics
- 7.3.1 Synthetic Biologics Profile
- 7.3.2 Synthetic Biologics Main Business
- 7.3.3 Synthetic Biologics Microbiome Drugs Products, Services and Solutions
- 7.3.4 Synthetic Biologics Microbiome Drugs Revenue (US$ Million) & (2020-2025)
- 7.3.5 Synthetic Biologics Recent Developments
- 7.4 Finch Therapeutics
- 7.4.1 Finch Therapeutics Profile
- 7.4.2 Finch Therapeutics Main Business
- 7.4.3 Finch Therapeutics Microbiome Drugs Products, Services and Solutions
- 7.4.4 Finch Therapeutics Microbiome Drugs Revenue (US$ Million) & (2020-2025)
- 7.4.5 Finch Therapeutics Recent Developments
- 7.5 PureTech
- 7.5.1 PureTech Profile
- 7.5.2 PureTech Main Business
- 7.5.3 PureTech Microbiome Drugs Products, Services and Solutions
- 7.5.4 PureTech Microbiome Drugs Revenue (US$ Million) & (2020-2025)
- 7.5.5 PureTech Recent Developments
- 7.6 Synlogic
- 7.6.1 Synlogic Profile
- 7.6.2 Synlogic Main Business
- 7.6.3 Synlogic Microbiome Drugs Products, Services and Solutions
- 7.6.4 Synlogic Microbiome Drugs Revenue (US$ Million) & (2020-2025)
- 7.6.5 Synlogic Recent Developments
- 7.7 Enterome BioScience
- 7.7.1 Enterome BioScience Profile
- 7.7.2 Enterome BioScience Main Business
- 7.7.3 Enterome BioScience Microbiome Drugs Products, Services and Solutions
- 7.7.4 Enterome BioScience Microbiome Drugs Revenue (US$ Million) & (2020-2025)
- 7.7.5 Enterome BioScience Recent Developments
- 7.8 4D Pharma
- 7.8.1 4D Pharma Profile
- 7.8.2 4D Pharma Main Business
- 7.8.3 4D Pharma Microbiome Drugs Products, Services and Solutions
- 7.8.4 4D Pharma Microbiome Drugs Revenue (US$ Million) & (2020-2025)
- 7.8.5 4D Pharma Recent Developments
- 7.9 Second Genome
- 7.9.1 Second Genome Profile
- 7.9.2 Second Genome Main Business
- 7.9.3 Second Genome Microbiome Drugs Products, Services and Solutions
- 7.9.4 Second Genome Microbiome Drugs Revenue (US$ Million) & (2020-2025)
- 7.9.5 Second Genome Recent Developments
- 7.10 Ferring
- 7.10.1 Ferring Profile
- 7.10.2 Ferring Main Business
- 7.10.3 Ferring Microbiome Drugs Products, Services and Solutions
- 7.10.4 Ferring Microbiome Drugs Revenue (US$ Million) & (2020-2025)
- 7.10.5 Ferring Recent Developments
- 7.11 C3 Jian
- 7.11.1 C3 Jian Profile
- 7.11.2 C3 Jian Main Business
- 7.11.3 C3 Jian Microbiome Drugs Products, Services and Solutions
- 7.11.4 C3 Jian Microbiome Drugs Revenue (US$ Million) & (2020-2025)
- 7.11.5 C3 Jian Recent Developments
- 7.12 Rebiotix
- 7.12.1 Rebiotix Profile
- 7.12.2 Rebiotix Main Business
- 7.12.3 Rebiotix Microbiome Drugs Products, Services and Solutions
- 7.12.4 Rebiotix Microbiome Drugs Revenue (US$ Million) & (2020-2025)
- 7.12.5 Rebiotix Recent Developments
- 7.13 MicroBiome Therapeutics LLC
- 7.13.1 MicroBiome Therapeutics LLC Profile
- 7.13.2 MicroBiome Therapeutics LLC Main Business
- 7.13.3 MicroBiome Therapeutics LLC Microbiome Drugs Products, Services and Solutions
- 7.13.4 MicroBiome Therapeutics LLC Microbiome Drugs Revenue (US$ Million) & (2020-2025)
- 7.13.5 MicroBiome Therapeutics LLC Recent Developments
- 7.14 Metabiomics
- 7.14.1 Metabiomics Profile
- 7.14.2 Metabiomics Main Business
- 7.14.3 Metabiomics Microbiome Drugs Products, Services and Solutions
- 7.14.4 Metabiomics Microbiome Drugs Revenue (US$ Million) & (2020-2025)
- 7.14.5 Metabiomics Recent Developments
- 7.15 Ritter Pharmaceuticals
- 7.15.1 Ritter Pharmaceuticals Profile
- 7.15.2 Ritter Pharmaceuticals Main Business
- 7.15.3 Ritter Pharmaceuticals Microbiome Drugs Products, Services and Solutions
- 7.15.4 Ritter Pharmaceuticals Microbiome Drugs Revenue (US$ Million) & (2020-2025)
- 7.15.5 Ritter Pharmaceuticals Recent Developments
- 7.16 Symberix
- 7.16.1 Symberix Profile
- 7.16.2 Symberix Main Business
- 7.16.3 Symberix Microbiome Drugs Products, Services and Solutions
- 7.16.4 Symberix Microbiome Drugs Revenue (US$ Million) & (2020-2025)
- 7.16.5 Symberix Recent Developments
- 7.17 OpenBiome
- 7.17.1 OpenBiome Profile
- 7.17.2 OpenBiome Main Business
- 7.17.3 OpenBiome Microbiome Drugs Products, Services and Solutions
- 7.17.4 OpenBiome Microbiome Drugs Revenue (US$ Million) & (2020-2025)
- 7.17.5 OpenBiome Recent Developments
- 7.18 Azitra
- 7.18.1 Azitra Profile
- 7.18.2 Azitra Main Business
- 7.18.3 Azitra Microbiome Drugs Products, Services and Solutions
- 7.18.4 Azitra Microbiome Drugs Revenue (US$ Million) & (2020-2025)
- 7.18.5 Azitra Recent Developments
- 7.19 Symbiotix Biotherapies
- 7.19.1 Symbiotix Biotherapies Profile
- 7.19.2 Symbiotix Biotherapies Main Business
- 7.19.3 Symbiotix Biotherapies Microbiome Drugs Products, Services and Solutions
- 7.19.4 Symbiotix Biotherapies Microbiome Drugs Revenue (US$ Million) & (2020-2025)
- 7.19.5 Symbiotix Biotherapies Recent Developments
- 7.20 Vedanta Biosciences
- 7.20.1 Vedanta Biosciences Profile
- 7.20.2 Vedanta Biosciences Main Business
- 7.20.3 Vedanta Biosciences Microbiome Drugs Products, Services and Solutions
- 7.20.4 Vedanta Biosciences Microbiome Drugs Revenue (US$ Million) & (2020-2025)
- 7.20.5 Vedanta Biosciences Recent Developments
- 7.21 Metabogen
- 7.21.1 Metabogen Profile
- 7.21.2 Metabogen Main Business
- 7.21.3 Metabogen Microbiome Drugs Products, Services and Solutions
- 7.21.4 Metabogen Microbiome Drugs Revenue (US$ Million) & (2020-2025)
- 7.21.5 Metabogen Recent Developments
8 Industry Chain Analysis
- 8.1 Microbiome Drugs Industrial Chain
- 8.2 Microbiome Drugs Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Raw Materials Key Suppliers
- 8.2.3 Manufacturing Cost Structure
- 8.3 Midstream Analysis
- 8.4 Downstream Analysis (Customers Analysis)
- 8.5 Sales Model and Sales Channels
- 8.5.1 Microbiome Drugs Sales Model
- 8.5.2 Sales Channel
- 8.5.3 Microbiome Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
- 10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.1.1 Research Programs/Design
- 10.1.1.2 Market Size Estimation
- 10.1.1.3 Market Breakdown and Data Triangulation
- 10.1.2 Data Source
- 10.1.2.1 Secondary Sources
- 10.1.2.2 Primary Sources
- 10.1.1 Methodology/Research Approach
- 10.2 Author Details
- 10.3 Disclaimer
